Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Asthma
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Asthma
    Asthma a Significant Risk Factor for Complications In Children With H1N1 - (DGNews)
    Genotypes Do Not Modify Lung Function In Response to Asthma Treatment - (DGNews)
    Inhaled Ciclesonide Improves Asthma Control: Presented at ACAAI - (DGDispatch)
    TopAbstracts in Asthma 11/16/2009 - (DGNews)
    Mometasone Plus Formoterol Appears Safe in Severe Persistent Asthma: Presented at ACAAI - (DGDispatch)

    News archive

     Recent webcasts/CME - Asthma
    • Balancing Patient-Related Factors With Safety and Efficacy to Optimize the Treatment of COPD
    • PreAnesthetic Assessment of the Child with A Cold or Asthma
      Work-Exacerbated Asthma
      Asthma Treatment: Step-Down and As-Needed Use of Inhaled Corticosteroids
      Role of the Pharmacist in Optimizing the Management of Asthma: Focus on Patient Education with Inhalation Devices

      Webcasts/CME archive

       Recent cases - Asthma
        Glucocorticoid Hypersensitivity as a Rare but Potentially Fatal Side Effect of Paediatric Asthma Treatment: A Case Report
        A Case of Lactic Acidosis Complicating Assessment and Management of Asthma
        Role of Vasopressin in the Treatment of Anaphylactic Shock in a Child Undergoing Surgery for Congenital Heart Disease: A Case Report
        Isolated Left Lung Aplasia with Bronchial Asthma
        Two Cases of Asthma in Handicapped Elderly Persons in which Assisted Inhalation Therapy was Effective

        Cases archive
          




        my personal edition > asthma > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Desloratadine Relieves Both Seasonal Allergic Rhinitis And Nasal Congestion

        A DGReview of :"Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion."
        Annals of Allergy, Asthma, & Immunology

        12/10/2002
        By Harvey McConnell


        Desloratadine produces significant relief from the signs and symptoms of seasonal allergic rhinitis (SAR), as well as nasal congestion, say researchers in the United States.

        Their four -week, multi-centre, parallel-group, double-blind study, directed by Dr W E Berger and colleagues at the Southern California Research, Mission Viejo, California, and collaborators in the Desloratadine Study Group, also found improvement of symptoms of seasonal allergic asthma.

        The clinicians point out that while antihistamines relieve most symptoms of SAR, an exception is concomitant relief of nasal congestion, which, in turn, is often the most troublesome symptom among patients. A significant treatment advance would be a non- sedating antihistamine that significantly decreases nasal congestion and improves SAR symptoms.

        A cohort of 331 patients with SAR and mild seasonal allergic asthma were enrolled to test the safety and efficacy of desloratadine 5 mg once a day compared with placebo. All patients evaluated their SAR and asthma symptoms twice a day, and recorded 12-hour reflective and instantaneous severity evaluation scores.

        The primary measure of treatment efficacy with desloratadine was the difference from baseline in AM/PM reflective total symptom scores. Clinicians also analyzed the changes among each member of the cohort of their SAR and asthma symptoms.

        The researchers found that desloratadine, when compared with placebo, produced a significant reduction in mean AM/PM reflective total symptom scores for SAR. This difference began with the first dose of the drug and continued throughout days one to 15 (-4.90 compared with -2.98) and days one to 29 (-5.47 compared with -3.73).

        Desloratadine significantly decreased AM/PM reflective total asthma symptom scores for days 1 to 15. and AM/PM reflective nasal congestion scores over days one to 15, and days one to 29. The clinicians found that desloratadine was safe and well tolerated; by the patients, and adverse events were similar overall among treated patients to those on placebo.
        Ann Allergy Asthma Immunol 2002; 89(5):485-91. "Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion."

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send